Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Related Articles
EMBARK on XTANDI – Advanced Prostate Cancer OncLive
Sponsored by Astellas Pharma US, Inc. and Pfizer Inc. Neal Shore, MD, FACS GenesisCare US Myrtle Beach, South Carolina Stephen Freedland, MD Warschaw, Robertson, Law…
Registration
Registration details for AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Special Session explores considerations behind breast cancer drug approvals, trials – SABCS Meeting News
Panelists discussed recent U.S. Food and Drug Administration approvals, plus the importance of monitoring ovarian toxicity in breast cancer clinical trials.
LSU Health Professor, Dr. Lucio Miele, Appointed as Director of LSU-LCMC Health Cancer Center
Lucio Miele, MD, PhD of LSU has been appointed as director of the LSU-LCMC Health Cancer Center.
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer
Nature Cancer – Sears and colleagues found that ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated…
Adoptive cell therapies in thoracic malignancies: a comprehensive review
Clinical and Translational Oncology – This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T…
Can White Wine Increase Your Risk for Skin Cancer?
Recent studies have suggested some surprising things (not beaming from the center of our solar system) that might increase your risk for skin cancer. We…
Adding camrelizumab to chemotherapy improves outcomes in triple-negative breast cancer
SAN ANTONIO — The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response for certain patients with triple-negative breast cancer. Camrelizumab (SHR-1210,…
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Key PointsForimtamig exhibits superior potency compared with other GPRC5D- and BCMA-targeting TCBs.Forimtamig combination with TCBs and CELMoDs prevents tu
